Swisse Vitamins

Therapeutic Goods Act 1989

I, Larry Kelly, Co-ordinator, Monitoring and Compliance Group, Therapeutic Goods Administration and delegate of the Secretary to the Department of Health and Ageing for the purposes of sections 42DF(1) and 42DK(1) of the Therapeutic Goods Act 1989 (the Act) give notice that the restricted representation described in paragraph (a) below has been approved for use in advertisements directed to consumers, for the medicines identified in paragraph (b) provided the conditions identified in paragraph (c) and (d) are met:

1. Representations to the effect that advertisements to consumers for the medicines described in paragraph (b) may refer to: "diabetes".
2. Swisse Ultiboost Odourless Fish Oil (ARTG: 164154); Swisse Ultiboost Wild Salmon Oil (ARTG: 164560); Swisse Ultiboost Wild Krill Oil (ARTG: 168778); Swisse Ultiboost Wild Fish Oil (ARTG: 174560); Swisse Ultiboost High Strength Wild Fish Oil (ARTG: 174630); Swisse Ultiboost Liquid Wild Fish Oil (ARTG: 175894); Swisse Odourless High Strength Wild Fish Oil (ARTG: 179201); Swisse Ultiboost Wild Fish Oil Concentrate (ARTG: 179232).
3. "Diabetes" may be used by Swisse Vitamins Pty Ltd to allow inclusion of the Baker IDI Heart & Diabetes Institute logo on the label, and in the advertising, of the medicines identified in paragraph (b) above.
4. The claims made in the advertisements must not extend beyond their intended purpose on the Australian Register of Therapeutic Goods. The advertisements in which the representations are made must comply with the Act, the Therapeutic Goods Regulations 1990 and the Therapeutic Goods Advertising Code 2007, as amended from time to time and must also advise consumers to seek advice from their medical practitioner or healthcare professional.

Dated this 22nd day of August 2011

Larry Kelly
Delegate of the Secretary to the Department of Health and Ageing; and
Co-ordinator
Monitoring and Compliance Group